| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
20,430,000 |
| Market
Cap: |
1.37(B) |
| Last
Volume: |
2,387,520 |
Avg
Vol: |
2,380,888 |
| 52
Week Range: |
$38.04 - $69.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ANI Pharmaceuticals is a bio-pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Co.'s products include: Candesartan Hydrochlorothiazide, Fenofibrate, Fluvoxamine, Hydrocortisone Enema, Lithium Carbonate ER, Mesalamine, Propranolol ER, Terbutaline, and Vancomycin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
133,940 |
429,766 |
488,178 |
1,059,214 |
| Total Sell Value |
$12,125,219 |
$37,903,299 |
$41,334,916 |
$77,194,579 |
| Total People Sold |
6 |
13 |
14 |
16 |
| Total Sell Transactions |
12 |
26 |
40 |
98 |
| End Date |
2025-08-19 |
2025-05-18 |
2024-11-17 |
2023-11-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Walsh Patrick D |
Director |
– • – |
2025-11-13 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,000 |
58,405 |
|
- |
|
| Walsh Patrick D |
Director |
– • – |
2025-11-13 |
4 |
S |
$86.88 |
$750,904 |
D/D |
(8,643) |
61,405 |
|
- |
|
| Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
• – – |
2025-11-13 |
4 |
AS |
$87.27 |
$34,908 |
D/D |
(400) |
75,274 |
|
- |
|
| Gassert Chad |
SVP - CORP. DEV. & STRATEGY |
• – – |
2025-11-13 |
4 |
S |
$88.00 |
$8,272 |
I/I |
(94) |
158,490 |
|
- |
|
| Gassert Chad |
SVP - CORP. DEV. & STRATEGY |
• – – |
2025-11-12 |
4 |
S |
$89.07 |
$1,304,163 |
I/I |
(14,642) |
158,584 |
|
- |
|
| Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
• – – |
2025-10-13 |
4 |
AS |
$90.09 |
$36,036 |
D/D |
(400) |
75,674 |
|
- |
|
| Davis Krista |
SVP, CHIEF HR OFFICER |
• – – |
2025-09-19 |
4 |
AS |
$98.04 |
$98,040 |
D/D |
(1,000) |
60,186 |
|
- |
|
| Davis Krista |
SVP, CHIEF HR OFFICER |
• – – |
2025-09-12 |
4 |
D |
$97.71 |
$167,084 |
D/D |
(1,710) |
61,186 |
|
- |
|
| Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
• – – |
2025-09-12 |
4 |
AS |
$98.42 |
$39,368 |
D/D |
(400) |
76,074 |
|
- |
|
| Pera Antonio R |
Director |
– • – |
2025-09-03 |
4 |
S |
$94.94 |
$692,302 |
D/D |
(7,292) |
22,660 |
|
- |
|
| Leonard Matthew J |
Director |
– • – |
2025-08-25 |
4 |
S |
$90.62 |
$229,087 |
D/D |
(2,528) |
6,864 |
|
- |
|
| Davis Krista |
SVP, CHIEF HR OFFICER |
• – – |
2025-08-22 |
4 |
S |
$91.10 |
$160,609 |
D/D |
(1,763) |
62,896 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2025-08-21 |
4 |
S |
$90.44 |
$4,792,235 |
I/I |
(52,988) |
431,920 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2025-08-20 |
4 |
S |
$90.27 |
$4,243,773 |
I/I |
(47,012) |
484,908 |
|
- |
|
| Pera Antonio R |
Director |
– • – |
2025-08-20 |
4 |
S |
$89.73 |
$486,426 |
D/D |
(5,421) |
29,952 |
|
- |
|
| Thoma Jeanne |
Director |
– • – |
2025-08-18 |
4 |
S |
$88.87 |
$1,920,370 |
D/D |
(21,540) |
23,405 |
|
- |
|
| Leonard Matthew J |
Director |
– • – |
2025-08-18 |
4 |
S |
$88.17 |
$611,635 |
D/D |
(6,937) |
9,392 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2025-08-15 |
4 |
S |
$87.15 |
$4,618,079 |
I/I |
(52,990) |
531,920 |
|
- |
|
| Walsh Patrick D |
Director |
– • – |
2025-08-15 |
4 |
S |
$89.05 |
$801,450 |
D/D |
(9,000) |
70,048 |
|
- |
|
| Gassert Chad |
SVP - CORP. DEV. & STRATEGY |
• – – |
2025-08-15 |
4 |
S |
$86.97 |
$1,739,400 |
I/I |
(20,000) |
173,226 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2025-08-14 |
4 |
S |
$89.48 |
$4,206,455 |
I/I |
(47,010) |
584,910 |
|
- |
|
| Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
• – – |
2025-08-13 |
4 |
AS |
$88.87 |
$35,548 |
D/D |
(400) |
76,474 |
|
- |
|
| Carey Stephen P. |
SVP & CFO |
• – – |
2025-08-12 |
4 |
S |
$86.07 |
$4,303,500 |
D/D |
(50,000) |
180,863 |
|
- |
|
| Carey Stephen P. |
SVP & CFO |
• – – |
2025-08-12 |
4 |
OE |
$46.49 |
$2,324,500 |
D/D |
50,000 |
230,863 |
|
- |
|
| Gutwerg Ori |
SVP, GENERICS |
• – – |
2025-08-12 |
4 |
S |
$86.53 |
$508,191 |
D/D |
(5,873) |
84,024 |
|
- |
|
479 Records found
|
|
Page 1 of 20 |
|
|
0.14 (0.21%) 
